rotigotine


Also found in: Wikipedia.

rotigotine

an antiparkinson agent.
indication This drug is used to treat idiopathic Parkinson's disease.
contraindications Defibrillation, MRI, and known hypersensitivity to this drug prohibit its use.
adverse effects Adverse effects of this drug include drowsiness, hallucinations, headache, malaise, paresthesia, vertigo, confusion, dizziness, dyskinesia, fatigue, fever, insomnia, sudden sleep onset, edema, hypertension, sinus tachycardia, orthostatic hypotension, dyspepsia, anorexia, constipation, vomiting, xerostomia, weight gain, urinary incontinence, dermatitis, erythema, rash, pruritus, purpura, arthralgia, and back pain. A life-threatening side effect is anaphylaxis. A common side effect is nausea.
References in periodicals archive ?
8 sgb v for products containing the substance rotigotine (atc code n04bc09) within the period from 12.
24-hour Efficacy Profile of Rotigotine in Patients with Advanced Parkinson's Disease: A Post-hoc Analysis
Currently a number of companies are in the process of trialling rotigotine, lisuride and apomorphine TDD systems for Parkinson's and Restless Leg Syndrome (RLS) patients.
These findings confirm and extend those of several previous reports in the literature, but none of the dopamine receptor agonists--pramipexole, ropinirole, cabergoline, bromocriptine, rotigotine, and apomorphine--currently carry a boxed warning about the potential for developing severe impulse control disorders.
This rate of augmentation with use of rotigotine is significantly lower than other dopamine agonists.
This edition has new drugs, including aclidinium bromide, felbamate, icosapent ethyl, linaclotide, peginesatide acetate, perampanel, rotigotine, and teriflunomide, and updated group monographs for antipsychotic agents, benzodiazepenes, calcium channel blocking agents, estrogens, macrolides, opioid analgesics, proton pump inhibitors, selective serotonin reuptake inhibitors, and serotonin 5-HT1 receptor agonists.
The dopamine receptor agonist rotigotine significantly reduced symptoms of restless legs syndrome in a multicenter placebo-controlled trial.
The former police officer claimed he had never had the urge to bet until sign-ing up for the trial of Rotigotine patches at the Southern General hospital in Glasgow in 2002.
In Europe, some forms of Parkinson's disease are now being treated with the rotigotine patch.
5 mg 3X/day Low blood pressure, (Parlodel 5 mg nausea, edema, [R]) confusion, dry mouth, depression, headaches Rotigotine 2mg/ One 2 mg Nausea, application Transdermal 24hrs patch a day site reactions, System 4 mg/ somnolence, dizziness, (Neupro 24hrs headache, vomiting, [R]) 6 mg/ sleep attacks, 24hrs insomnia.
Therapeutic use: Rotigotine (20-23) is a nonergolinic dopamine agonist that is indicated for the management of signs and symptoms of early stage idiopathic Parkinson's disease.